NCT05508633View on ClinicalTrials.gov

The Instant Efficacy and Safety of Alverine in Decreasing Portal Hypertension: an Exploratory Pilot Study

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 28, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Portal Hypertension
Interventions
DRUG

Alverine Citrate

Low-dose group: Alverine (60 mg, 1 capsule) High-dose group: Alverine (120 mg, 2 capsules) The drug is orally given with 200 ml warm water after measurement of the baseline portal pressure.

Trial Locations (1)

200001

Shanghai Changzheng hospital, Shanghai

All Listed Sponsors
lead

Shanghai Changzheng Hospital

OTHER